发明名称 Methods of assaying sensitivity of cancer stem cells to therapeutic modalities
摘要 The present invention is directed to methods of measuring the proliferative ability of individual patient cancer stem cells. The present invention provides a method for treating a cancer patient according to an assay of the individual patient's tumor's cancer stem cell sensitivity, by measuring the proliferative ability of cancer stem cells from the patient. By the methods of the present invention it is possible to treat individual cancer stem cells presented in tumor cells. Methods of detecting and enumerating cancer stem cells in hybrid spheroids comprised of fibroblasts and tumor cells are also provided by the present invention. The present invention also contemplates a method for drug and other treatment development, wherein the effects of a drug or combination of drugs or other treatments are determined on the individual patient's cancer stem cells.
申请公布号 US9410944(B2) 申请公布日期 2016.08.09
申请号 US201514597735 申请日期 2015.01.15
申请人 The Research Foundation for The State University of New York 发明人 Lange Christopher S.;Djordjevic Bozidar;Rotman Marvin Z.
分类号 G01N33/50;C12N5/00;G01N33/574 主分类号 G01N33/50
代理机构 Scully, Scott, Murphy & Presser, P.C. 代理人 Scully, Scott, Murphy & Presser, P.C.
主权项 1. A method for treating a cancer patient according to an assay of the patient's cancer stem cell (CSC) sensitivity, the method for treating comprising: measuring a proliferative ability of the CSCs in the presence and absence of a drug or treatment, the method for measuring comprising the steps of: obtaining a single cell suspension containing stem cells from the patient's tumor, engulfing the stem cell in a spheroid of fibroblast, detecting those spheroids within which the stem cell has grown at least 10 divisions to show the presence of cancer stem cells, assaying the growth of the single cancer stem cell in the spheroids in suspension in the presence and absence of the drug or treatment, and providing the drug or treatment to the patient if there is a decrease in the fraction of cancer stem cell growth in the presence of the drug or treatment compared with control.
地址 Albany NY US
您可能感兴趣的专利